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Identification and characterization 
of serovar-independent immunogens 
in Actinobacillus pleuropneumoniae
Fabio Antenucci1, Cyrielle Fougeroux2, Janine T. Bossé3, Zofia Magnowska1, Camille Roesch4, Paul Langford3, 
Peter Johannes Holst2 and Anders Miki Bojesen1*
Abstract 
Despite numerous actions to prevent disease, Actinobacillus pleuropneumoniae (A. pleuropneumoniae) remains a major 
cause of porcine pleuropneumonia, resulting in economic losses to the swine industry worldwide. In this paper, we 
describe the utilization of a reverse vaccinology approach for the selection and in vitro testing of serovar-independent 
A. pleuropneumoniae immunogens. Potential immunogens were identified in the complete genomes of three A. pleu-
ropneumoniae strains belonging to different serovars using the following parameters: predicted outer-membrane sub-
cellular localization; ≤ 1 trans-membrane helices; presence of a signal peptide in the protein sequence; presence in all 
known A. pleuropneumoniae genomes; homology with other well characterized factors with relevant data regarding 
immunogenicity/protective potential. Using this approach, we selected the proteins ApfA and VacJ to be expressed 
and further characterized, both in silico and in vitro. Additionally, we analysed outer membrane vesicles (OMVs) of A. 
pleuropneumoniae MIDG2331 as potential immunogens, and compared deletions in degS and nlpI for increasing yields 
of OMVs compared to the parental strain. Our results indicated that ApfA and VacJ are highly conserved proteins, nat-
urally expressed during infection by all A. pleuropneumoniae serovars tested. Furthermore, OMVs, ApfA and VacJ were 
shown to possess a high immunogenic potential in vitro. These findings favour the immunogen selection protocol 
used, and suggest that OMVs, along with ApfA and VacJ, could represent effective immunogens for the prevention of 
A. pleuropneumoniae infections in a serovar-independent manner. This hypothesis is nonetheless predictive in nature, 
and in vivo testing in a relevant animal model will be necessary to verify its validity.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Actinobacillus pleuropneumoniae (A. pleuropneumoniae) 
is a Gram-negative bacterium causing respiratory dis-
ease in pigs worldwide. A. pleuropneumoniae outbreaks 
are a constant threat to the pig farming industry, and are 
estimated to reduce the expected revenues in pig produc-
tion by an average of 6.4€ per pig in affected herds [1]. To 
date, A. pleuropneumoniae has been divided into 16 sero-
vars and 2 biovars, according to capsular antigens and 
nicotinamide dinucleotide (NAD) requirements [2–4], 
respectively. The spatiotemporal prevalence of individual 
serovars has been shown to vary, both regionally and 
over time [5].
The first generation of vaccines developed against A. 
pleuropneumoniae was based on inactivated whole cells 
(bacterins). Although in some cases effective in pre-
venting both colonization and morbidity, these vaccines 
offered protection against little more than the specific 
serovar used for immunization [6, 7]. A step forward 
was made with the characterization of the Apx toxins, a 
set of four pore-forming cytolysins (Apx I-IV) centrally 
involved in A. pleuropneumoniae pathogenesis, and 
secreted by all A. pleuropneumoniae serovars in various 
combinations [3, 8]. Vaccines based on Apx toxins elicit 
a strong humoral response and are able to effectively 
reduce morbidity in vaccinated animals [9–12], but fail 
in preventing colonization and thus create the risk of the 
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spreading of disease by asymptomatic carriers [6, 11, 13]. 
Nonetheless, vaccines based on Apx toxins in combina-
tion with various outer membrane (OM) proteins (see 
[6] for a complete review of A. pleuropneumoniae OM 
immunogens) are the most widely used for the preven-
tion of A. pleuropneumoniae infection. Thus, despite the 
availability of vaccines for A. pleuropneumoniae, their 
efficacy is challenged by limited prevention of host colo-
nization [10, 14] or cross-serovar protection [11, 13, 15]. 
Hence a major challenge impeding development of an 
effective vaccine has been to identify immunogens capa-
ble of preventing colonization of the host by all known A. 
pleuropneumoniae serovars as well as the severity of the 
disease.
The selection of immunogens for vaccine development 
has for decades been a rather laborious process, usually 
requiring the isolation and testing of hundreds of poten-
tial immunogens from cultures with subsequent iden-
tification of the genes involved in their expression, and 
finally production of the chosen immunogens for in vitro 
and in  vivo testing [16]. The advent of bioinformatics 
and the sequencing of bacterial genomes have allowed 
researchers to invert this workflow and identify instead 
potential immunogens at a genetic level. Once identified, 
candidate immunogens can be easily expressed using 
suitable vectors for subsequent testing. This alternative 
workflow has quite fittingly been called reverse vacci-
nology (RV) [17, 18], and has offered immunologists the 
opportunity to significantly reduce the workload tradi-
tionally necessary for vaccine development [19].
Similar to RV, bacterial outer membrane vesicles 
(OMVs) represent a revolution in the way non-live vac-
cines are now conceived and developed. The OMVs are 
vesicles secreted by the majority of Gram-negative bacte-
ria that serve numerous biological functions, from cargo 
delivery to immune modulation [20, 21]. The OMVs are 
secreted during all phases of bacterial growth, and vary 
in size between 20 and 300  nm for Gram-negative bac-
teria [22, 23]. Secretion of OMVs has been proven to 
be negatively regulated by various genes, inactivation 
of which often leads to an enhanced secretion of OMVs 
[24]. Being released from the bacterial OM, OMVs gener-
ally represent antigenic properties very similar to intact 
bacteria. In addition, OMVs have a significant adjuvant 
potential due to the presence of lipopolysaccharides 
(LPS) and immunomodulatory proteins on their surface 
[25, 26]. The relatively high molecular mass of OMVs also 
allows for more cost-effective purification methods, as 
compared to recombinant antigens [27], leading to lower 
vaccine production costs [28, 29]. Additionally, the struc-
ture and biogenesis of OMVs offer the possibility to engi-
neer them in order to add desired antigens, either to their 
surface or as cargo [30, 31]. However, immunization with 
OMVs also presents some risks. The presence of LPS on 
OMVs, for example, could pose a threat to the vaccinated 
individual, potentially causing Systemic Inflammatory 
Response Syndrome (SIRS) after immunization [32].
Both OMVs and proteins identified using RV are con-
sidered promising vaccines commodities, and have 
so far been utilized commercially in the widely used 
vaccine against Neisseria meningitidis [33]. Here we 
employ a similar methodology for the identification of 
serovar-independent immunogens as a first step in the 
development of a broadly protective vaccine against A. 
pleuropneumoniae.
Materials and methods
Bacterial strains, genomes, and sequence analysis
The A. pleuropneumoniae strains and accession num-
bers for genomes used in this investigation are listed in 
Table  1. Unless otherwise stated, all sequence analysis 
programmes were used with default parameters. The 
pan-proteomes extracted from genomes of A. pleuro-
pneumoniae JL03, L20 and AP76 strains (serovars 3, 5b, 
and 7, respectively) were analysed by PSORTb v3.0 [34]. 
Proteins whose subcellular localization was predicted 
as “OuterMembrane” with a score  >  9.00/10.00 were 
included in a preliminary candidate immunogen list 
(Additional file 1). The conservation of candidate immu-
nogen genes across all published A. pleuropneumoniae 
Table 1 A. pleuropneumoniae genomes and strains included in this study
NCBI accession numbers are provided.
NA: non available.
Strain Serovar Genome assembly Accession Number (NCBI) Function
A. pleuropneumoniae JL03 3 CP000687.1 In silico identification of potential immunogens
A. pleuropneumoniae L20 5b CP000569.1
A. pleuropneumoniae AP76 7 CP001091.1
A. pleuropneumoniae MIDG2331 8 NZ_LN908249.1 OMV isolation and characterization
A. pleuropneumoniae MIDG2331 ΔnlpI 8 NA
A. pleuropneumoniae HK361 2 NA In vitro immunogenicity assessment
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genomes (those available in Genbank as of 14/02/17) was 
verified using BLASTn. Minimum and maximum con-
servation rates were noted in the preliminary candidate 
immunogen list (Additional file 1), as was the predicted 
presence or lack of a signal peptide, as detected by Sig-
nalP 4.1 [35], and the number of transmembrane helices 
(TMHs), as predicted by the TMHMM Server v. 2.0 [36]. 
Candidates with > 1 predicted TMH were discarded from 
further analysis. Preliminary candidate immunogens 
were screened for available data regarding their biologi-
cal function and/or immunogenicity, narrowing down 
the initial list to 9 candidate immunogens (Table  2). 
Finally, ApfA and VacJ were chosen for expression and 
characterisation. The ApfA and VacJ three-dimensional 
protein structures were predicted using the I-TASSER 
server [37]. Highest confidence models were chosen as 
predicted structures (ApfA model C-score: −0.40; VacJ 
model C-score: −3.74). 
Construction of ΔdegS & ΔnlpI mutants
The A. pleuropneumoniae serotype 8 MIDG2331 strain 
was engineered for the construction of individual ΔnlpI 
and ΔdegS mutants. The nlpI or degS genes of the wild 
type (wt) strain were each replaced with a synthesised 
(Eurofins Genomics) trimethoprim resistance cassette 
consisting of the drfA14 gene from plasmid pM3389T 
[38] under control of the A. pleuropneumoniae sodC pro-
moter [39], and followed by the 9 bp sequence required 
for efficient uptake of DNA during natural transfor-
mation of A. pleuropneumoniae [40]. Gene replace-
ment constructs were designed by In-Fusion cloning, 
with the dfrA14 cassette flanked by approx. 500 bases 
of sequence upstream and downstream of the gene to 
be replaced, as previously described [41]. Sequences 
were amplified using AccuPrime Taq DNA high-fidelity 
Polymerase (ThermoFisher Scientific). Briefly, primers 
(degS_left_for  +  degS_right_rev; nlpI_left_for  +  nlpI_
right_rev; Table 3) were designed to amplify the left and 
right sequences flanking the gene to be deleted, with 
15  bp extensions to allow directional cloning into the 
linear vector pJET1.2/blunt (ThermoFisher Scientific). 
The resulting plasmids, pJET-degS and pJET-nlpI were 
opened by inverse polymerase chain reaction (PCR), 
using degS_left_rev  +  degS_right_for and nlpI_left_
rev +  nlpI_right_for primer pairs (Table  3). The dfrA14 
cassette was amplified and cloned into the inverse-ampli-
fied pJET-degS and pJET-nlpI plasmids, using primers 
with 15  bp extensions matching the ends of the line-
arized constructs (dfrA14_degS_for +  dfrA14_degS_rev; 
dfrA14_nlpI_for + dfrA14_nlpI_rev; Table 3). The result-
ing plasmids, pJETΔdegS::dfrA14 and pJETΔnlpI::dfrA14 
were linearized by digestion with FastDigest XbaI 
restriction enzyme (ThermoFisher Scientific) prior to 
natural transformation into A. pleuropneumoniae sero-
type 8 strain MIDG2331 [42], as previously described 
[41]. Transformants were selected on BHI (brain–heart 
infusion)-NAD containing 10  μg/mL trimethoprim, and 
the gene replacements were confirmed by PCR using 
primers designed to verify the location of the dfrA14 
cassette insertion (degS_test  +  dfrA14_test_for; nlpI_
test + dfrA14_test_rev; see Table 3).
OMV isolation and analysis
For isolation of OMVs from A. pleuropneumoniae 
MIDG2331 wt, ΔdegS and ΔnlpI clones, 600 mL of BHI-
NAD broth was inoculated for each with a 1/10 volume 
of overnight (ON) culture (to an initial  OD600  =  0.1 
(OD: optical density) and incubated at 37 °C/200 rpm for 
Table 2 Candidate immunogen list
NCBI accession numbers are provided.
Protein Accession Number (NCBI) Function/putative role in virulence
ApfA YP_001053581.1 Fimbrial subunit protein, demonstrated role in A. pleuropneumoniae colonization and virulence [56]
APP7_2042 WP_005616333.1 Putative ligand-gated iron transporter
HecB ACE61667.1 Hemolysin activation protein and putative virulence factor in Arcobacter butzleri [67]
HgbA YP_001053746.1 Hemoglobin binding protein, A. pleuropneumoniae ΔhgbA mutants exhibit an attenuated virulence [54]
Irp ABN74015.1 Iron-regulated OM receptor/transporter possibly involved in hemin transport, upregulated in A. pleuro-
pneumoniae after colonisation [58]
OstA YP_001053661.1 Organic solvent tolerance protein in Helicobacter pilori. OstA inactivation causes altered membrane perme-
ability, sensitivity to organic solvent and susceptibility to antibiotics [68]
PepN ABN74424.1 Multi-subunit transmembrane metalloprotease able to degrade porcine IgA and IgG, expressed during A. 
pleuropneumoniae infection in vivo [55]
SlyB ABN73145.1 Outer membrane lipoprotein, contributes to cell envelope integrity in Burkholderia multivorans [69] and is 
linked to the stress response to Mg2 + depletion [70]
VacJ YP_001054603.1 OM lipoprotein, Pasteurella multocida VacJ protein moderately immunogenic and protective when inocu-
lated in vivo [63]
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approx. 7  h (late exponential phase). Culture superna-
tants, obtained following centrifugation (6000 g, 20 min, 
4  °C), were filtered through 0.45 μm Minisart sterile fil-
ters (Sartorius) before concentration of OMVs by Hydro-
static Filtration (HF), using a modified version of the 
protocol described by Musante et  al. [43]. Briefly, for 
each sample, the filtered supernatant was loaded into a 
dialysis membrane (Biotech CE Dialysis Tubing, 1000 kD 
molecular weight cut-off (MWCO), 31  mm Flat-width; 
Spectrum Labs) and encased vertically inside a Plexiglas 
column, where the hydrostatic pressure of the fluid itself 
provided the force needed to concentrate all particles 
above the membrane’s MWCO. The column, sealed with 
transparent film at the top to help prevent dehydration of 
the membrane, and with a bottle below to collect the flow 
through, was placed at 4 °C ON. The concentrated super-
natant was recovered from inside the membrane the 
following day, filtered through a 0.45  μm filter, and re-
suspended in sterile phosphate buffered saline (PBS) to 
a final volume of 300 mL prior to being re-concentrated 
in a second round of HF. The following day, the concen-
trate was filtered through a 0.45  μm filter and statically 
dialysed 1:1000 in sterile PBS (3  h, 4  °C). The dialysed 
samples were then further concentrated using Amicon 
Ultra-15 Centrifugal Filter Units (Merck Millipore) to a 
final volume of 3 mL (i.e. 200-fold concentration).
Samples were analysed by transmission electron 
microscopy (TEM). Carbon-coated laminae were sus-
pended into the OMV solutions for a few seconds and 
soaked with a droplet of 2% (w/v) phosphotungstic acid. 
Grids were soaked into a Sellotape/Chlorophorm solu-
tion to increase adherence and then placed on the lami-
nae. After 1–2  min, the Grids were removed and left 
to dry on filter paper. Once dried, stained grids were 
examined using a Philips CM100 Transmission Electron 
Microscope (Philips). Additionally, aliquots of the OMV 
samples were quantified by tunable resistive pulse sens-
ing (TRPS) using a qNano device (Izon Sciences Ltd) fol-
lowing the protocol recommended by the operator [44]. 
Data were analyzed using the proprietary data capture 
and analysis software, Izon Control Suite V.3.3.2.2001.
Expression and purification of recombinant ApfA and VacJ
The apfA and vacJ genes were amplified from genomic 
DNA using Phusion Hot Start II DNA high-fidelity 
Polymerase (ThermoFisher Scientific) and cloned into 
the pET-44 Ek/LIC Vector (Merck Millipore) by In-
Fusion directional cloning (Clontech). Briefly, prim-
ers were designed to open the vector by inverse PCR 
(pET44_apfA_rev  +  pET44_apfA_for), and to amplify 
the genes (apfA_pET44_for  +  apfA_pET44_rev; vacJ_
pET44_for  +  vacJ_pET44_rev; see Table  3). The gene 
specific primers did not include the start or stop codons, 
as these were supplied by the vector. For all primers, 
15  bp extensions were added to the 5′ ends, providing 
reciprocal regions of complementarity (30  bp total) for 
In-Fusion cloning. The In-Fusion reactions were initially 
transformed into Stellar competent cells (Clontech) and 
verified before being transformed into E. coli BL21(DE3)
pLysS competent cells, with selection on BHI agar sup-
plemented with 100  µg/mL Ampicillin. Selected clones 
were screened by PCR and sequencing, and plasmids 
with the correct inserts were designated pApfA  exprn and 
pVacJ  exprn (n = 1–3).
For large-scale purification of expressed ApfA and 
VacJ proteins, the appropriate clones were inocu-
lated into 800  mL of pre-warmed 2YT-Amp broth, 
using a 1/10 dilution of an ON starter culture, and 
incubated at 37  °C, 150  rpm, until  OD600 reached 
0.5–08. At this point, the incubation temperature 
was shifted to 20  °C, and 20  min later protein expres-
sion was induced by addition of 400  μL of 1  M IPTG 
Table 3 Primers used in this study
Lower case letters indicate nucleotides modified from the target sequence in 
order to reduce primer secondary structure formation.
Primer Sequence (5′– > 3′)
degS_left_for GAATTCCTGCAGCCCGCGAACGGCTAAATCTATATGATG
degS_left_rev CCAAGGTTGAAACGAAACCTAGTGCAATCGCTTGTAC
degS_right_for TTGACGGAGGGCTTTGGCGAATTTCCGGAACTATAATGC
degS_right_rev ACTAGTGGATCCCCCCGCAACCTCACGATTTCTATCTC
nlpI_left-for GAATTCCTGCAGCCCGCGTGATGGAACAAGCGATTC
nlpI_left-rev CCAAGGTTGAAACGAGCATCAAGAAGCGAAGGT-
GAAAC
nlpI_right-for TTGACGGAGGGCTTTACGTGGTGGTAGCAATGTTG
nlpI_right-rev ACTAGTGGATCCCCCTTGTAGTGCAGAGAGGTCTAACG
dfrA14-degS_for CGATTGCACTAGGTTTCGTTTCAACCTTGGTGTTTGG
dfrA14-degS_rev TTCCGGAAATTCGCCAAAGCCCTCCGTCAAATTTAT-
TACC
dfrA14-nlpI_for TTCGCTTCTTGATGCTCGTTTCAACCTTGGTGTTTGG
dfrA14-nlpI_rev TTGCTACCACCACGTAAAGCCCTCCGTCAAATTTATTACC
degS_test AATAATGACCGAACACATCC
nlpI_test ATTTCGTCCGCTTCATCC
dfrA14_test-for TCGTTTCAACCTTGGTGTTTGG
dfrA14_test-rev AAAGCCCTCCGTCAATTTTATTACC
apfA_pET44_for GTCCCaCGaGGaAGCCAgAAgCTAAGTCTTATTCGACCa
apfA_pET44_rev ACTTcATTAACATTAGTTTATCGCgCAGAAATTTGCC
pET44_apfA_rev AAGACTTAGcTTcTGGCTtCCtCGtGGGACCAG
pET44_apfA_for TTCTGcGCGATAAAcTAATGTTAATgAA-
GTTGGGCGTTCCT
vacJ_pET44_for GTCCCaCGaGGaAGCAAgTTAAAgCAATTAAGgTTAG-
TAGCC
vacJ_pET44_rev ACTTcATTAACATTAATCAATgTCTTTcAATTCTTCTTCGG
pET44_vacJ_rev TAATTGcTTTAAcTTGCTtCCtCGtGGGACCAG
pET44_vacJ_for TTgAAAGAcATTGATTAATGTTAATgAA-
GTTGGGCGTTCCT
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(isopropil-β-d-1-tiogalattopiranoside). Cultures were 
then left to incubate ON at 20  °C, 150 rpm. Cell pellets 
were harvested by centrifugation (10 000 g, 10 min, 4 °C) 
and then kept on ice. Pellets were resuspended in lysis 
buffer (2 mL/g of pellet) and sonicated twice (80% Power, 
5 pulsations, 5  min, 4  °C, 25  W effective). Cell lysates 
were centrifuged (40 000 g, 30 min, 4  °C), and superna-
tants were filtered on ice through 0.2 μm filters. A list of 
the non-commercial buffers used is provided in Addi-
tional file 2.
The recombinant proteins were isolated from the 
supernatants by immobilized ion metal affinity chroma-
tography (IMAC) using the ÄKTAxpress chromatogra-
phy system (GE Healthcare). Supernatants were loaded 
and run on HisTrap SP-HP 5  mL columns (GE Health-
care) following the manufacturer’s recommendations. 
The extinction coefficients of the recombinant proteins 
were calculated using the ExPASy ProtParam tool [45] 
and uploaded to the ÄKTAxpress managing program, 
in order to identify (by  OD280 absorbance) the fractions 
containing proteins after purification. Selected protein 
fractions were pooled on ice, transferred to a 6–8 kD 
dialysis membrane (Spectra/por), and dialysed ON in 4 l 
PBS. Protein profiles of the purified fractions were com-
pared to that of the initial filtered supernatant by electro-
phoresis under denaturing conditions using NuPAGE™ 
(PAGE: polyAcrylamide gel electrophoresis) 4–12% Bis–
Tris Protein sodium dodecyl sulphate (SDS) Gel (Ther-
moFisher Scientific), run for 1  h at 180  V, and stained 
with Coomasie Blue.
Tags were removed from the purified proteins by cleav-
age with human plasma thrombin (Merck Millipore)(~2 
U thrombin/μg of protein, 37  °C, ON), and separation 
by size exclusion chromatography (SEC). Proteins were 
loaded and run on Superdex 75 PG columns (GE Health-
care) using the ÄKTAxpress chromatography system. 
Fractions containing ApfA and VacJ proteins were identi-
fied, collected and dialyzed as described above.
Analysis of serum samples by ELISA
Control pig serum samples were obtained from Dan-
ish pig herds participating in the specific pathogen free 
(SPF) system. All herd are tested for A. pleuropneumo-
niae serovars 1, 2, 5, 6, 7, 10 and 12, respectively, using 
ELISA (enzyme-linked immunosorbent assay) methods 
previously described [46]. Convalescent sera from pigs 
experimentally infected with A. pleuropneumoniae sero-
type 2 HK361 were also used. All animals were otherwise 
classified as pathogen-free. Details regarding all sera used 
in this study are provided in Table 4.
Antibody (IgG) responses to purified ApfA and VacJ 
were determined by ELISA. Briefly, 96-well flat bottom 
plates (TPP) were coated with 100 ng of protein/well in 
PBS, and incubated at 4  °C ON. Pig sera (negative con-
trols and samples known to be positive for serovars 2, 
6 and 12, respectively) were diluted threefold between 
1:500 and 1:1 093 500 in diluent buffer, and incubated for 
1  h at room temperature (RT). Bound antibodies were 
detected with peroxidase labelled rabbit anti-pig IgG 
(ThermoFisher Scientific) at a 1:15 000 dilution, followed 
by colorimetric detection  (OD450) with TMB2 PLUS2 
substrate (Kem-En-Tec Diagnostics), according to the 
manufacturer’s protocol. A list of the non-commercial 
buffers used is provided in Additional file  2. The four 
data sets (Control, A. pleuropneumoniae serotype 12, 2, 
6) from ApfA and VacJ ELISA assays were transformed 
to log10 values and analysed by D’Agostino and Pear-
son ominubus normality test to verify the assumption 
of Gaussian distribution of the data sets (alpha =  0.05). 
Data sets were subsequently converted to area under 
curve (AUC) values and analysed by Ordinary one-way 
ANOVA (P < 0.05) to verify their statistical significance. 
When overall statistical significance was achieved by 
ANOVA, data were analysed by post hoc Holm-Sidak 
test to assess statistical differences between individual 
groups and controls. P  <  0.05 were again considered 
statistically significant. All statistical analyses were per-
formed using GraphPad Prism 6.0c (GraphPad Software, 
La Jolla California USA). A summary of the statistical 
results obtained is provided in Additional file 3.
2D SDS‑PAGE and Western blot
Proteins from OMV isolates of A. pleuropneumoniae 
2331 wt and ΔnlpI mutant, containing equal number of 
vesicles, were purified by Wessel-Flüge extraction [47]. 
Prior to IsoElectric Focusing (IEF), immobilized pH 
gradient (IPG) strips (pH 4–7, 7  cm, GE Life Sciences) 
were rehydrated in DeStreak rehydration solution (GE 
Life Sciences)(1.5% IPG buffer, pH 4–7, ON). The sam-
ples were applied using the cup-loading method and IEF 
was performed at a total of 7 kVh per strip on an Ettan 
IPGphor isoelectric focusing unit (GE Life Sciences). IPG 
strips were subsequently reduced, alkylated and proteins 
were separated in duplicates by SDS-PAGE as a second 
dimension using NuPAGE 4–12% Bis–Tris ZOOM gels 
(Invitrogen) in running conditions as described above 
Table 4 Animal sera used in this study
Serum Serovar specificity Mode of infection
App 2 A. pleuropneumoniae serovar 2 Natural
App 6 A. pleuropneumoniae serovar 6 Natural
App 12 A. pleuropneumoniae serovar 12 Natural
Naive // Uninfected
App HK361 A. pleuropneumoniae HK361: serovar 2 Experimental
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for standard SDS-PAGE. The other set of gels was trans-
ferred to polyvinylidene difluoride (PVDF) membranes 
using an  iBlot® Gel Transfer Device (Thermofisher Scien-
tific) for Western blotting. Pig sera from controls and ani-
mals that were challenged with live A. pleuropneumoniae 
HK361 cells were used as  1aAb, 1:2000 dilution. A com-
mercial Anti-Swine IgG (H  +  L)-Alkaline Phosphatase 
antibody (Sigma Aldrich) was used as  2aAb, 1:10  000 
dilution. Bands were revealed by 30  min incubation 
with dissolved SIGMAFAST™  BCIP®/NBT (5-bromo-
4-chloro-3-indolyl-phosphate/nitro blue tetrazolium) 
tablets (Sigma Aldrich). A list of the non-commercial 
buffers used is provided in Additional file 2.
Results
In silico selection of conserved immunogens
A list of all potential immunogens initially identified is 
shown in Additional file 1. Only proteins predicted to be 
localised in the OM, and having ≤ 1 TMH, were included; 
likely secreted candidates were discarded. Details regard-
ing predicted function and immunogenicity (based on 
published data) were used to narrow down the list of 
potential immunogens to 9 candidates (Table  2). From 
the 9 candidates, ApfA and VacJ proteins were selected 
for expression and in vitro characterization.
Preparation of recombinant proteins and OMVs
Both apfA and vacJ were successfully cloned into the 
pET-44 Ek/LIC vector, resulting in plasmids pET-44_
apfA and pET-44_vacJ. Expression of protein from E. 
coli strains harbouring these plasmids yielded a total of 
46 mg and 18 mg protein for ApfA and VacJ, respectively, 
prior to tag removal. Following tag removal, two protein-
containing fractions were isolated (Figure  1), however 
purified proteins were derived only from the fractions 
showing higher concentration and purity (i.e. the second 
fraction for each of ApfA and VacJ). The final protein 
yields were 7.4 mg for ApfA, and 4.25 mg for VacJ.
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(SEC). A ApfA SEC; B VacJ SEC; Input: Proteins + cleaved tags before SEC; Fractions 1–2: Isolated fractions of purified ApfA and VacJ proteins after 
SEC. ApfA and VacJ proteins are indicated by black arrows. The size of selected bands of the protein marker in kilodaltons (kDa) is shown. ApfA theo-
retical molecular weight: 20 kDa; VacJ theoretical molecular weight: 27 kDa; Human thrombin molecular weight: 37 kDa.
Page 7 of 12Antenucci et al. Vet Res  (2017) 48:74 
The OMVs isolated by HF from wt, ΔdegS and 
ΔnlpI mutants were analysed by TEM (Figure  2) and 
precisely quantified and measured by TRPS analy-
sis (Figure  3). Both ΔdegS and ΔnlpI mutants showed 
increased OMV secretion as compared to the wt. The 
size distribution of the OMVs was also affected, with 
a wider variation in diameter range recorded for both 
mutants (Figure 3).
Figure 2 Transmission electron microscopy (TEM) analysis of A. pleuropneumoniae outer membrane vesicles (OMVs). TEM images show 
OMVs isolated from A. pleuropneumoniae MIDG2331 wild-type (A) and ΔdegS (B), ΔnlpI (C) mutants. Red arrows indicate OMVs.
Figure 3 TRPS analysis of OMVs. TRPS analysis of OMVs from A. pleuropneumoniae MIDG2331 wt (A), ΔdegS (B) and ΔnlpI (C) mutants. Size distri-
bution and concentration of OMV samples are shown on individual graphics and resumed on the table on the right side of the figure.
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Assessment of in vitro immunogenicity
Convalescent sera from animals naturally infected with 
A. pleuropneumoniae serovars 2, 6 or 12, respectively, 
showed a significantly higher median IgG response 
against both ApfA and VacJ than the control sera from 
uninfected pigs (Figure 4). Statistical analysis of the data 
sets showed the significance of the differences observed 
between groups in IgG levels for both ApfA and VacJ 
(P  <  0.05; Additional file  3). Similarly, the Western blot 
(WB) analysis with sera from animals experimentally 
infected with A. pleuropneumoniae HK361 (serovar 
2) showed a strong IgG response to both wt and ΔnlpI 
OMVs, and the presence of several particularly immuno-
genic proteins (Figure 5, only ΔnlpI OMVs shown).
Discussion
The development of new vaccines is predicted to become 
increasingly important in the fight against bacterial 
pathogens, due to the emergence of multidrug-resistant 
strains, and the dwindling number of new antimicrobials 
Co
ntr
ol
Ap
p 1
2
Ap
p 2
Ap
p 6
0
1
2
3
Area Under Curve (AUC)
A
re
a 
(U
)
IgG response to ApfA
*
*
*
Co
ntr
ol
Ap
p 1
2
Ap
p 2
Ap
p 6
0
1
2
3
Area Under Curve (AUC)
A
re
a 
(U
)
IgG response to VacJ
*
*
*
A B 
Figure 4 IgG response to ApfA and VacJ proteins. IgG response in convalescent pigs against ApfA (A) and VacJ (B) proteins. IgG response is 
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Figure 5 IgG response to OMVs. IgG response to A. pleuropneumoniae 2331 ΔnlpI OMVs was assessed by Western blot analysis using pig sera 
pooled from the same group of pigs, before (A) and after a challenge with live A. pleuropneumoniae HK 361 cells (B). Bands size in kilodaltons (kDa) 
of the protein marked used are provided on the right side of the figure.
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released on the market during the recent decades [48]. 
Accordingly, several new strategies for the identification 
of potential immunogens have been proposed and imple-
mented [16]. Most of these strategies make use of the 
wide range of genome sequences and bioinformatic tools, 
and are sometimes collectively characterized as “immu-
noinformatics” [49]. Despite their obvious hypotheti-
cal nature, these computational predictions and in silico 
analyses have proven effective in the development of at 
least one commercial vaccine [33].
Subcellular localization is intuitively important when 
selecting potential immunogens. Intracellular or peri-
plasmic antigens are not highly accessible to the host 
immune system, and usually do not play a significant 
role in the development of adaptive immunity against 
extracellular bacteria [50]. On the other hand, secreted 
proteins are usually highly immunogenic and quite 
often centrally involved in the bacterial pathogenesis 
(e.g. toxins), but being detached from the cell they fail 
in many instances in providing protection against bacte-
rial colonization when administered as vaccines [13, 15, 
51]. These and other previously described considera-
tions led us to focus our analysis on OM proteins. Some 
of the identified candidates are A. pleuropneumoniae 
proteins involved in iron acquisition from the host (see 
Table 2), and limiting access to free iron has been proven 
to severely affect bacterial growth during infection [52, 
53]. A. pleuropneumoniae represents no exception, and 
for instance the inactivation of the hgbA gene has been 
linked to reduced virulence in vivo [54]. PepN is another 
interesting candidate immunogen in our list, a protease 
able to degrade porcine IgA and IgG [55]. It is intuitive to 
understand how targeting antibody degradation could be 
beneficial in reducing A. pleuropneumoniae resistance to 
the host immune system. However, the most promising 
vaccine candidate antigens that we chose to investigate in 
this study were ApfA and VacJ.
Type IV fimbrial subunit protein ApfA is a well char-
acterised virulence factor in A. pleuropneumoniae, whose 
potential as an immunogen has been preliminarily inves-
tigated in swine and mouse models of infection [11, 56, 
57]. ApfA is an OM pilin involved in the early stages of 
host colonization, and its operon has been proven to be 
overexpressed during cell adhesion in  vitro [58]. Cell 
adhesion represents one of the first steps involved in the 
colonisation of host surfaces by a pathogenic bacterium 
[59], providing an ideal target for immunisation of the 
host with a view to blocking infection. To date, ApfA’s 
potential as a protective immunogen remains controver-
sial, with some data suggesting it may be able to confer 
partial protection [11, 56], while others suggest ApfA may 
interfere with the development of an adaptive response 
when included in a multicomponent vaccine formulation 
[57]. Our data confirmed ApfA conservation among all 
known A. pleuropneumoniae serovars. Furthermore, 
we demonstrated that ApfA is not only expressed by A. 
pleuropneumoniae in  vitro or during a challenge in an 
induced animal model, but also during a natural infec-
tion in pigs, eliciting a rather marked humoral immune 
response in animals infected by at least 3 different A. 
pleuropneumoniae serovars not previously investigated. 
Finally, protein domain profiling of ApfA allowed us to 
identify a highly conserved helical domain, common to 
many pilins across species, that could be potentially used 
as an OM “anchor” for the construction of chimeras for 
antigen enrichment of the bacterial OM or OMVs.
VacJ (virulence-associated chromosome locus J) is 
an OM lipoprotein partially conserved among several 
Gram-negative pathogenic bacteria, including A. pleu-
ropneumoniae. VacJ is part of a proposed phospholipid 
transporter (VacJ/Yrb ABC transporter), the inactiva-
tion or deletion of which has recently been shown to 
increase OMV secretion in some species [60]. In A. pleu-
ropneumoniae, VacJ has been shown to be involved in 
OM integrity, serum resistance and biofilm formation 
[61]. As its name suggests, VacJ has been proposed as 
potential immunogen, and proven necessary for intra-
cellular motility of Shigella flexneri [62]. Furthermore, 
the protective potential of a VacJ immunization has been 
described in at least one case, for Pasteurella multocida 
[63], whose VacJ protein shares 59% homology with the 
A. pleuropneumoniae homolog. As for ApfA, our data 
have shown that VacJ is highly conserved, expressed by 
A. pleuropneumoniae during a natural infection, and able 
to induce a specific immune response in pigs.
The potential use of OMVs as immunogens has been 
extensively investigated in several bacterial species, 
including other Pasteurellaceae [64]. Bacterial OMVs 
have been shown to contain most of the antigens embed-
ded in the OM, including LPS, toxins and other surface 
antigens [20]. Most notably, A. pleuropneumoniae OMVs 
were previously shown to carry Apx toxins and proteases 
[65]. Our data provides further insight into the immuno-
genicity of A. pleuropneumoniae OMVs, with WB profiles 
indicating the presence of several highly immunogenic 
antigens, recognised by sera from animals infected with 
A. pleuropneumoniae serovars different than that used 
for isolation of the OMVs. The identity of these antigenic 
determinants is yet to be clarified, but it is likely that they 
include conserved proteins and virulence factors in addi-
tion to the Apx toxins and proteases previously described 
[63]. Furthermore, the choice of HF as purification tech-
nique allowed the concentration of large volumes of bac-
terial cell-free culture supernatants, increasing OMV 
yield when compared to gel filtration and gradient cen-
trifugation methods, traditionally employed in OMV 
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isolation [27]. The ability to purify large batches of OMVs 
may prove very useful in the process of standardizing 
immunization protocols, where a large number of ani-
mals need to be vaccinated with the same sample.
In conclusion, our data support the potential of in silico 
identification of immunogens, and confirm the predicted 
high immunogenicity of A. pleuropneumoniae OMVs. 
Both ApfA and VacJ were shown to be expressed dur-
ing infection by all the A. pleuropneumoniae serovars 
tested and thus may offer the long sought cross-serovar 
immunological potential. Accordingly, we hypothesize 
that OMVs, as well as ApfA and VacJ proteins, could 
be administered individually or as a combined vaccine 
for prevention of infection in pigs against all known A. 
pleuropneumoniae isolates. Nonetheless, in silico and 
in vitro analysis can only provide predictive information 
regarding the immunogenic potential of ApfA, VacJ and 
OMVs. In some instances in fact OM proteins have been 
described to produce a deleterious effect when employed 
as immunogens to vaccinate pigs [66], and accordingly 
in vivo testing in a relevant animal model (swine) will be 
required to verify the effective potential of ApfA, VacJ 
and OMVs as immunogens.
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